Multiple Myeloma
Conference Coverage
Myeloma patients over age 70 can benefit from auto-HC transplant
ORLANDO – Researchers said all myeloma patients should be referred a transplant center, regardless of age.
Conference Coverage
Bispecific CAR T-cells yield high response rate in relapsed/refractory myeloma
ORLANDO – Duration of response, manageable safety support further investigation of dual-targeted strategy, according to investigator.
Conference Coverage
High complete response rate seen with novel CAR-T for myeloma
ORLANDO – A CAR T product targeting B-cell maturation antigen, one of several in development, was associated with a 100% overall response rate.
Conference Coverage
ASH preview: Key themes include tackling CAR T obstacles, sickle cell advances, VTE
New findings take aim at CAR T-cell therapy-related obstacles and highlight potential new paths forward.
From the Journals
Early lenalidomide may delay progression of smoldering myeloma
Researchers said the findings from the phase 3 study support early treatment as the new standard of care in patients with high-risk smoldering...
Latest News
Foundation launches direct-to-patient registry in multiple myeloma
The registry is designed to give information back to patients, but physicians may be able to use the database to identify high-risk patients and...
From the Journals
Levofloxacin prophylaxis improves survival in newly diagnosed myeloma
Levofloxacin looks like a promising addition to therapy, but the researchers cautioned that antibiotic resistance must be considered.
From the Journals
SEER analysis reveals medication adherence factors in newly diagnosed myeloma
The study found that more than a third of older patients with multiple myeloma had poor adherence to lenalidomide.
Conference Coverage
What is the optimal duration of maintenance in myeloma?
SAN FRANCISCO – Dr. Yvonne A. Efebera and Dr. Nina Shah debate whether patients with multiple myeloma should receive maintenance until progression...
Conference Coverage
Study finds no standard for treatment discontinuation in myeloma
BOSTON – Reasons for treatment discontinuation varied by regimen and line of therapy.
Conference Coverage
Second-generation anti-BCMA CAR T-cell therapy shows promise in myeloma trial
BOSTON – None of the patients in the trial developed grade 3 or higher cytokine-release syndrome.